Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer
Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer, With Focus on Background Parenchymal Enhancement
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sébastien MOLIERE, MD
- Phone Number: 33 3 88 12 78 65
- Email: sebastien.moliere@chru-strasbourg.fr
Study Contact Backup
- Name: Marie-Noëlle ROEDLICH, MD
- Phone Number: 33 3 88 12 78 65
- Email: marie-noelle.roedlich@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67098
- Recruiting
- Service Imagerie 1
-
Contact:
- Sébastien MOLIERE, MD
- Phone Number: 33 3 88 12 78 65
- Email: sebastien.moliere@chru-strasbourg.fr
-
Principal Investigator:
- Sebastien MOLIERE, MD
-
Sub-Investigator:
- Marie-Noëlle ROEDLICH, MD
-
Sub-Investigator:
- Isabelle ODDOU, MD
-
Contact:
- Marie-Noëlle ROEDLICH, MD
- Phone Number: 33 3 88 12 78 65
- Email: marie-noelle.roedlich@chru-strasbourg.fr
-
Sub-Investigator:
- Carole MATHELIN, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients
- Patients with breast cancer treated with neoadjuvant chemotherapy
- Patients with pre- and post-chemotherapy MRI
- Patients who have given their agreement to use their data for research purposes.
Exclusion Criteria:
- Refusal to participate in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence or absence of of pathologic enhancement of breast by MRI
Time Frame: 1 hour after the realization of the MRI
|
This work concerns 110 patients treated with neoadjuvant chemotherapy for breast cancer and having received a breast MRI in pre and post-chemiotherapy at the Hautepierre Hospital.
|
1 hour after the realization of the MRI
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sébastien MOLIERE, MD, University Hospital, Strasbourg, France
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6788
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.